Recently, Budesonide Suspension for Inhalation (Tianqing Suchang^®), from SBP Group's (1177.HK) core enterprise Chia Tai Tianqing, received a GMP certificate and related marketing authorization from the Eurasian Economic Union (EAEU). The latest export order was delivered simultaneously, marking further recognition of Chia Tai Tianqing's production quality system for inhalation preparations and its international supply capability. This also adds new vitality to the company's expansion of respiratory products into overseas markets. 

Budesonide Suspension for Inhalation is an inhaled corticosteroid drug commonly used in clinical practice for respiratory disorders such as bronchial asthma. It acts directly on the lungs via nebulized inhalation, has a strong local anti-inflammatory effect, and is the top-selling drug for chronic respiratory diseases in China. 

As the first domestically produced Budesonide Suspension for Inhalation, Tianqing Suchang^® was approved in 2020. Focusing on the R&D, production, and quality control of inhalation preparations, Chia Tai Tianqing has continuously advanced its technological accumulation and industrialization capabilities. Related achievements have won the "Jiangsu Provincial Science and Technology Progress Award" and have gained unanimous recognition from medical institutions and patients in clinical practice. Passing the GMP certification this time will allow the drug to benefit more patients in countries along the "Belt and Road" and promote exchange and cooperation in the medical and health fields. 

During this on-site inspection, official inspectors conducted a comprehensive and rigorous audit of Chia Tai Tianqing's quality system, production control, material management, laboratory control, and documentation, giving high recognition to the company's quality management system. At the same time, in response to overseas order demand, Chia Tai Tianqing rapidly advanced the coordination of product export supply, synergistically promoting processes from production scheduling and quality release to international logistics. The export order for Budesonide Suspension for Inhalation has been delivered on schedule, achieving a rapid implementation of commercial export. 

Chia Tai Tianqing will continue to advance the international layout of R&D, production, registration, and commercialization, and continuously enhance its quality management system and supply chain capabilities that meet international standards. Based on product quality and clinical value, it will actively expand international cooperation, allowing more high-quality Chinese drugs to go overseas and provide new treatment options for patients in countries along the "Belt and Road" and other regions.